Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
09:32 ET | 4982 | 39.7 |
09:36 ET | 300 | 39.56 |
09:41 ET | 100 | 39.54 |
09:43 ET | 16100 | 39.47 |
09:45 ET | 10200 | 39.655 |
09:50 ET | 2300 | 39.38 |
09:52 ET | 4900 | 39.475 |
09:54 ET | 500 | 39.455 |
09:56 ET | 1600 | 39.31 |
09:57 ET | 129 | 39.455 |
09:59 ET | 534 | 39.455 |
10:06 ET | 5400 | 39.365 |
10:10 ET | 400 | 39.35 |
10:12 ET | 12668 | 39.19 |
10:14 ET | 100 | 39.28 |
10:17 ET | 682 | 39.18 |
10:21 ET | 1600 | 39.24 |
10:24 ET | 100 | 39.31 |
10:26 ET | 140 | 39.4 |
10:30 ET | 200 | 39.345 |
10:32 ET | 200 | 39.305 |
10:33 ET | 100 | 39.305 |
10:35 ET | 100 | 39.26 |
10:37 ET | 7269 | 39.2701 |
10:39 ET | 1100 | 39.325 |
10:42 ET | 5508 | 39.325 |
10:44 ET | 3273 | 39.415 |
10:48 ET | 6100 | 39.44 |
10:53 ET | 600 | 39.48 |
10:55 ET | 1026 | 39.34 |
10:57 ET | 100 | 39.38 |
11:04 ET | 4700 | 39.41 |
11:06 ET | 100 | 39.39 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 3.0B | -14.5x | --- |
Apogee Therapeutics Inc | 2.9B | -25.0x | --- |
Summit Therapeutics Inc | 3.1B | -27.2x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Iovance Biotherapeutics Inc | 2.9B | -5.6x | --- |
IDEAYA Biosciences Inc | 3.1B | -20.5x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.